Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News


Innate Immunotherapeutics announces top-line results for trial of MIS416 in patients with secondary progressive multiple sclerosis

Summary:

- Initial analysis of Phase 2B trial data on a total enrolled patient population basis show no clinically meaningful or statistically significant differences in measures of neuromuscular function or patient-reported outcomes

- Further analysis to be undertaken on patients who adhered to the trial protocol (the per protocol population) and at the level of individual patient responses; expected to be reported within the next month. It is unlikely the result will significantly change

- Compassionate Use Program is continuing, pending the results of further analysis

- Investor conference call scheduled for 10.30 am AEST, Tuesday, June 27th, 2017

Innate Immunotherapeutics Limited (ASX Code:IIL) today announced that its Phase 2B randomised, double-blind, placebo-controlled trial of the efficacy and safety of MIS416 in the treatment of subjects with secondary progressive multiple sclerosis (SPMS) did not show clinically meaningful or statistically significant differences in measures of neuromuscular function or patient reported outcomes.


For further information please download PDF attached:
Download this document